GlassScriptPhysician profile
Sanda Maria Morar
NPI 1326155391
$14,257.69
in general payments reported to CMS, 2019-2025
73 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,153 · 2020: $2,775 · 2021: $3,466 · 2022: $1,022 · 2023: $1,405 · 2024: $212 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.41 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,769.04 | 2019-2024 | |
| Incyte Corporation | $1,094.29 | 2019-2024 | Monjuvi |
| Janssen Biotech, INC. | $906.05 | 2019-2023 | Tecvayli, Imbruvica, Darzalex |
| Astrazeneca Pharmaceuticals LP | $713.89 | 2019-2023 | Tagrisso |
| Amgen INC. | $450.44 | 2019-2023 | Vectibix |
| Emd Serono, INC. | $433.88 | 2019-2023 | Bavencio |
| Beigene USA, INC. | $382.23 | 2020-2023 | Brukinsa |
| Merck Sharp & Dohme LLC | $371.18 | 2019-2024 | Keytruda, Lynparza |
| Astellas Pharma US INC | $361.91 | 2019-2025 | Padcev |
| Celgene Corporation | $323.02 | 2019-2023 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $322.22 | 2019-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $285.41 | 2019-2023 | |
| Genzyme Corporation | $285.02 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $271.68 | 2019-2023 | Libtayo |
| Clovis Oncology, INC. | $255.53 | 2019-2022 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanda Morar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.